Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 312.7%

Posted by George Bondi on May 13th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 31,467 shares, a growth of 312.7% from the April 15th total of 7,624 shares. Based on an average daily trading volume, of 68,401 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Stock Report on INCR

InterCure Stock Up 3.2%

Shares of NASDAQ:INCR traded up $0.03 during trading on Wednesday, hitting $0.84. The company’s stock had a trading volume of 4,010 shares, compared to its average volume of 48,401. The company has a market capitalization of $45.71 million, a PE ratio of 27.87 and a beta of 1.24. InterCure has a fifty-two week low of $0.68 and a fifty-two week high of $1.77. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48. The stock’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $1.02.

InterCure (NASDAQ:INCR – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $23.15 million during the quarter.

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.